Exploring new avenues: Psychedelic‐assisted therapy for young people
British Journal of Clinical Pharmacology · 08.05.2026
DOI: 10.1002/bcp.70579 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift British Journal of Clinical Pharmacology, online erschienen am 08.05.2026. Verfasst von Ioanna Artemis Vamvakopoulou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK. Die Arbeit nennt 94 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Rates of mental illness in young people are increasing, whereas the development of novel mental health treatments has not significantly progressed. Psychedelic‐assisted therapy, using substances such as psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA), has shown potential in the treatment of mental illnesses in the adult population, including depression, anxiety and post‐traumatic stress disorder. Interest has been growing around the potential use of psychedelic‐assisted therapy to treat mental illness in adolescents. We present here a comprehensive review of all research focusing on children and young people, from experimental research of the 50s to observational and retrospective research focusing on traditional and Western non‐medical use. The limited available research so far suggests that psychedelics appear to be safe overall and may have the potential to improve mental wellbeing in young people. However, young people may be at more risk of experiencing anxiety, challenging experiences and ego dissolution, but more thorough clinical research is warranted. Moving forward, we suggest that psychedelic‐assisted therapy for young people should be administered within a rigorous ethical framework, where education of both the young people and their families is incorporated. Family involvement should be considered as part of the therapeutic framework. Lastly, avenues within the psychedelic space should be considered for young people, like the use of lower doses (psycholytic approach), which might lower the potential risks that are seen with high doses.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Psychiatry, Department of Brain Sciences, Imperial College London, London, UK.
ORCID-Profile: Ioanna Artemis Vamvakopoulou, Dasha Nicholls, David J Nutt, Martina Di Simplicio
Zitieren
APA
Vamvakopoulou, I. A., Nicholls, D., Nutt, D. J., & Di Simplicio, M. (2026). Exploring new avenues: Psychedelic‐assisted therapy for young people. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70579
Vancouver
Vamvakopoulou IA, Nicholls D, Nutt DJ, Di Simplicio M. Exploring new avenues: Psychedelic‐assisted therapy for young people. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70579
BibTeX
@article{Vamvakopoulou2026,
author = {Vamvakopoulou, Ioanna Artemis and Nicholls, Dasha and Nutt, David J and Di Simplicio, Martina},
title = {Exploring new avenues: Psychedelic‐assisted therapy for young people},
journal = {British Journal of Clinical Pharmacology},
year = {2026},
doi = {10.1002/bcp.70579}
}
EUVIMED